Protemix Raises $14.5M

San Diego-baed Protemix, a biopharmaceutical firm developing an oral treatment for diabetic heart failure, said today that it has closed on $14.5M in Series A financing. The funding was co-led by Novartis Venture Fund and NovaQuest, and also included prior investor Birnie Capital Ltd. The firm will use the funding to advance clinical development of the firm's lead product, and for other early stage programs in the firm's pipeline. More information »